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Abstract
Background: Our aim was to investigate the influence of FTS on human cellular and humoral immunity using a
randomized controlled clinical study in esophageal cancer patients.
Methods: Between October 2013 and December 2014, 276 patients with esophageal cancer in our department
were enrolled in the study. The patients were randomized into two groups: FTS pathway group and conventional
pathway group. The postoperative hospital stay, hospitalization expenditure, and postoperative complications were
recorded. The markers of inflammatory and immune function were measured before operation as well as on the
1st, 3rd, and 7th postoperative days (POD), including serum level of interleukin-6 (IL-6), C-reactive protein (CRP),
serum globulin, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA) and lymphocyte
subpopulations (CD3 lymphocytes, CD4 lymphocytes, CD8 lymphocytes and the CD4/CD8 ratio) in the patients
between the two groups.
Results: In all, 260 patients completed the study: 128 in the FTS group and 132 in the conventional group. We
found implementation of FTS pathway decreases postoperative length of stay and hospital charges (P < 0.05). In
addition, inflammatory reactions, based on IL-6 and CRP levels, were less intense following FTS pathway compared
to conventional pathway on POD1 and POD3 (P < 0.05). On POD1 and POD3, the levels of IgG, IgA, CD3
lymphocytes, CD4 lymphocytes and the CD4/CD8 ratio in FTS group were significantly higher than those in control
group (All P < 0.05). However, there were no differences in the level of IgM and CD8 lymphocytes between the two
groups.
Conclusions: FTS improves postoperative clinical recovery and effectively inhibited release of inflammatory factors
via the immune system after esophagectomy for esophageal cancer.
Trial registration: ChiCTR-TRC-13003562, the date of registration: August 29, 2013.
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Background
Since its introduction in the 1990s, the concept of fast-
track surgery (FTS) has gained widespread acceptance
and is now considered as a standard of care. FTS also
referred to as enhanced recovery after surgery (ERAS)
have been implemented in order to enhance recovery,
reduce morbidity and mortality rates, and shorten
hospital stay after major surgery. The aim of this novel
approach to perioperative patient care is to decrease the
perioperative stress response to the surgical trauma and
thereby leading to a decrease in complication rates in
surgery. These promising clinical results lead to the
question of whether the concept of FTS also results in
better-preserved immune function in the postoperative
course. Some researchers believe that FTS also has posi-
tive effects on the human immune system, which may
result in quicker recovery of postoperative immune
function [1]. Nevertheless, few clinical studies results
have reported the impact of FTS on human immunity.
Therefore, based on the hypothesis and present evidence
of the benefits of FTS, we prospectively studied 276
patients underwent esophagectomy for esophageal can-
cer who either received FTS pathway or conventional
pathway in the perioperative period. In addition to
clinical outcome parameters, we analysed the effects of
FTS on proinflammatory cytokine IL-6 and CRP levels
as well as immunoglobulin and lymphocyte subgroups
before surgery and on days 1, 3 and 5 after surgery.
Methods
Patients and procedures
This study was conducted in the Department of
Thoracic Surgery at Harbin Medical University Can-
cer Hospital from October 2013 to December 2014.
Inclusion criteria included: age ≥18 and ≤75 years,
American Society of Anesthesiologists (ASA) grade I/
II, body mass index (BMI) 18.5–27.5 kg/m2, resect-
able esophageal cancer (page 36, NCCN Guidelines
version 1.2013). However, we found in our previous
clinical study involving patients with confounding fac-
tors that such factors might have a great impact on
the results, such as immunological parameters for
both controlled and observational groups. Therefore,
some patients needed to be excluded from our study.
The exclusion criteria of the study were as follows:
patients with known immunological dysfunction
(advanced liver disease (decompensated cirrhosis, por-
tal hypertension or hepatocellular carcinoma), HIV in-
fection, hepatitis C virus infection), pulmonary
insufficiency (An acute or chronic condition marked
by impaired pulmonary function, characterized by ele-
vated carbon dioxide or decreased oxygen, or both),
unresectable esophageal cancer (page 36, NCCN
Guidelines version 1.2013), ASA III-IV, Karnofsky
index less than 60, BMI less than 18.5 kg/m2, and age
of 65–75 years with hypertension, diabetes, or vascu-
lar disease. Two hundred and seventy-six patients
who were clinically diagnosed as having esophageal
cancer were assigned to two groups comprising 138
patients each: FTS group and conventional group.
Enrolled patients were randomly assigned to two
groups using computer-generated random numbers.
For approximately equal allocation to the two treat-
ments, we took odd and even numbers to indicate
treatments A (FTS group) and B (conventional
group), respectively. The patients were admitted to
different peri-operative care wards based on the
computer-generated random numbers when they were
Fig. 1 Patient flow throughout the study
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admitted; specifically, 138 patients were randomized
to traditional protocol wards and 138 to the FTS
surgery wards.
Ten patients in the FTS group and 6 patients in the
conventional group failed to undergo FTS and
conventional pathway. Most of them did not undergo
esophagectomy as expected. The final study population
included 260 patients (Fig. 1). The relevant characteris-
tics of patients and the types of surgery are listed in
Table 1. Gastroscope and barium meal of the upper
gastrointestinal tract were systematically performed for
tumors before operations. All patients underwent further
work-up to assess the medical operability. This included
evaluation of pulmonary and cardiac function, cervical
and abdominal ultrasonography, chest computed tomog-
raphy, and hematological examinations.
The FTS pathway used was developed by our cooper-
ation team based on a previous protocol [2]. The princi-
ples of the FTS and conventional pathways are described
in Table 2, and the principles of the postoperative FTS
and conventional pathways are described in Table 3. The






Median age 56.43 ± 13.28 55.72 ± 10.34 0.252
Gender 0.973
Male 103 (80.5) 106 (80.3)
Female 25 (19.5) 26 (19.7)
Weight (kg) 67.53 ± 14.37 66.45 ± 13.56 0.448
BMI (kg/m2) 22.53 ± 2.85 22.89 ± 2.56 0.272
Operating time (min) 168.98 ± 30.62 172.33 ± 24.67 0.438
Blood loss (ml) 302.54 ± 88.48 312. 33 ± 76.73 0.727
Operative incision 0.749
One 44 (34.4) 48 (36.4)
Two 58 (45.3) 62 (46.9)
Three 26 (20.3) 22 (16.7)
TNM 0.773
I 39 (30.5) 36 (27.2)
II 71 (55.4) 79 (59.8)
III 18 (14.1) 17 (12.8)
IV 0 (0) 0 (0)
Pathology 0.737
Adenocarcinoma 7 (5.5) 8 (6.1)
Squamous cell carcinoma 116 (90.6) 121 (91.6)
Other 5 (3.9) 3 (2.3)
Tumor location 0.921
Upper esophagus 12 (9.4) 14 (10.6)
Mid esophagus 73 (57.0) 76 (57.6)
Distal esophagus 43 (33.6) 42 (31.8)
Neoadjuvant therapy 0.988
Yes 68 (53.1) 70 (53.0)




27 (39.7) 25 (35.7)
Neoadjuvant chemotherapy 41 (60.3) 45 (64.3)
pCR after Neoadjuvant
therapy
15 (22.1) 17 (24.2) 0.776
Surgical approach 0.953
Conventional thoracotomy 62 (48.4) 66 (50.0)
Hybrid VATS 41 (32.0) 42 (31.8)
Pure VATS 25 (19.6) 24 (18.2)
Variables were expressed as the mean ± SD
pCR pathologic complete response rates
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study was approved by the Research Ethics Committee
of Harbin Medical University, and written informed
consent was obtained from all subjects.
Clinical parameters
The post-operative hospital stay defined as time spent in
the hospital from the day of operation to the day of
hospital discharge, including readmission stay within
30 days postoperatively. The complications were defined
as atrial arrhythmia, anastomotic leak, ileus, pneumonia,
ARDS and incision infection. Readmission rate was also
recorded. Pain while coughing, staying in bed or during
exercise was judged by the patients three times daily
until day 5 after surgery using the numeric rating scale
Table 3 Daily guideline of postoperative care of patients with FTS pathway vs conventional pathway
Day FTS pathway Conventional pathway
POD1 Jejunostomy tube feeding 500 mL (starting at 20 mL/h)
Early postoperative mobilization program
(>2 h out of bed)
Physical therapy and nebulizers
Remove urine catheter
Head of bed put at 30°
Supply albumin
Chest tube to suction





POD2 Jejunostomy tube feeding 1000 mL (40 mL/h)
Chest tube to suction
Expand mobilization (>4 h out of bed)
Continue physical therapy and nebulizers
Continue supply albumin
Nasojejunal tube feeding 500 mL (starting at 20 mL/h)
Remove urine catheter
With help, sit in the chair 2 times during the day for at least 30 min each time
Gastrointestinal decompression
Closed thoracic drainage
POD3 Jejunostomy tube feeding 1500 mL (60–80 mL/h)
Remove chest tube
Remove epidural catheter
Expand mobilization (>6 h out of bed)
Continue physical therapy and nebulizers
Continue supply albumin
Nasojejunal tube feeding 1000 mL (40 mL/h)
Sit in the chair 3 times for at least 30–60 min each time.
With help, walk twice in the hallway.
Do deep breathing exercise
Remove nasogastric tube
Closed thoracic drainage
POD4 Gastrograffin opacification of upper gastrointestine
If swallow shows no leak, advance patient to oral drink
Jejunostomy tube feeding 1500 mL (60–80 mL/h)
Continue physical therapy and nebulizers
Education on aspiration precaution
Education on chewing and swallowing
Nasojejunal tube feeding 1000 mL (40 mL/h)
Sit in the chair 3 times today for at least 30–60 min each time.
Walk the length of the hallway 3 times
Continue to do breathing exercises
Closed thoracic drainage
POD5 Jejunostomy tube feeding 1500 mL (60–80 mL/h)
Advance patient to a full liquid diet
Continue aspiration precautions
Continue physical therapy and nebulizers
Nasojejunal tube feeding 1500 mL (60–80 mL/h)
Walk the length of the hallway 4–5 times. Sit in the chair 3 times today for at
least 30–60 min
Continue to do breathing exercises
POD6 Increase liquid diet
Decrease jejunostomy tube feeding
(500 ml or 1000 ml)
Continue aspiration precautions
Continue physical therapy and nebulizers
Nasojejunal tube feeding 1500 mL (60–80 mL/h)
Remove chest tube
Walk the length of the hallway 4–5 times. Sit in the chair 3 times today for at
least 30–60 min
Continue to do breathing exercises
POD7 Remove jejunostomy tube
Full liquid diet
Discharge home on soft diet and liquid diet
Continue aspiration precautions
Gastrograffin opacification of upper gastrointestine
If swallow shows no leak, advance patient to oral drink
Nasojejunal tube feeding 1500 mL (60–80 mL/h)
Expand mobilization (>4 h out of bed)
Continue to do breathing exercises
POD8 Increase liquid diet
Decrease jejunostomy tube feeding (500 ml or 1000 ml)
Expand mobilization (>6 h out of bed)
Continue to do breathing exercises
POD9 Remove nasojejunal tube
Full liquid diet
Expand mobilization (>6 h out of bed)
Continue to do breathing exercises
POD10-
11
Soft diet and liquid diet
Nearly out of bed
Observe whether there is delayed anastomotic leakage
POD12 Discharge home on soft diet and liquid diet
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(0, no pain to 10, maximum pain). The perioperative
hospital charges included surgery, anesthesia, drugs,
auxiliary examination (including laboratory and radi-
ology), and care costs, but didn’t include neoadjuvant
therapy costs.
Protocol for esophageal cancer
The diagnostic and therapeutic protocols for patients
with esophageal cancer at the authors’ institution is
based on NCCN Guidelines version 1.2013 (page 36–
37). Since the R0-resection rate and long-term outcome
of patients with T3/T4 tumors is poor with primary
resection, multimodal therapeutic concepts with pre-
operative chemotherapy or combined radiochemother-
apy or both are employed in these patients.
Pro-inflammatory parameters
Peripheral venous blood samples were collected in
serum collection tubes (Kabe) and were subsequently
centrifuged at 300 × g for 15 min at 4 °C and serum
samples were subsequently stored at −80 °C until
assayed for IL-6.
Circulating serum IL-6 levels were determined using
sandwich enzyme-linked immunosorbent assay (Bio-
source, Nivelles, Belgium) as described by the manufac-
turer. CRP was measured with the immunoturbidimetric
method (Olympus, Hamburg, Germany).
Immunological parameters
Blood samples were taken on the day before surgery as
well as on days 1, 3 and 5 after surgery. All blood samples
were taken from peripheral veins at 6 a.m., before break-
fast. The humoral immunologic factors tested in our study
included serum globulin, immunoglobulin G (IgG), im-
munoglobulin M (IgM), immunoglobulin A (IgA).
Lymphocyte subpopulation parameters
Lymphocyte subpopulations (CD3, CD4, and CD8 lym-
phocytes, and the CD4/CD8 ratio) were determined by
flow cytometry (Becton Dickinson, San Jose, CA, USA).
The monoclonal antibodies used for immunophenotyp-
ing were purchased from Becton Dickinson and conju-
gated to the fluorochromes, fluorescein isothiocyanate
or phycoerythrin. The fluorescence was measured using
a FACScalibur (Becton Dickinson) within 60 min of
processing of the samples. Fluorescent-activated cell
sorting analysis was carried out on a FACScalibur flow
cytometer. A minimum of 10,000 cells were measured
for each determination.
Table 4 Comparison of outcome of two group
Outcomes FTS group (n = 128) Conventional group (n =132) P value
Postoperative hospital stay (d) 7.62 ± 1.38 12.56 ± 1.92 0.000
Hospitalization expenditure (RMB) 35823.62 ± 3598.81 41032.73 ± 4013.32 0.000
Incision pain scale (NRS) 4.72 ± 1.94 7.66 ± 1.59 0.000
Morbidity 11 (8.6) 16 (12.1) 0.351
Atrial arrhythmia 2 3
Ileus 0 1
Pneumonia 3 4
Anastomotic leak 2 3
Incision infection 2 2
ARDS 2 3
Mortality 2 (1.6) 2 (1.5) 1.000
30-day readmission rate 3 (2.3) 3 (2.3) 1.000
Variables were expressed as the mean ± SD
The Numeric Rating Scale (NRS) is an 11–point (0–10) scale for patient self-reporting of pain. It is for adults and children 10 years old or older
RMB Ren Min Bi or China Yuan
Table 5 Comparison of inflammatory markers in two groups






Before surgery 53.83 ± 21.66 55.73 ± 20.37 0.585
POD1 121.74 ± 22.57 138.77 ± 21.53* 0.000
POD3 142.37 ± 25.09 154.90 ± 24.33* 0.035
POD7 116.70 ± 22.39 122.79 ± 25.64 0.412
CRP (μg/L)
Before surgery 4.97 ± 1.33 4.85 ± 1.43 1.000
POD1 65.57 ± 13.37 74.61 ± 14.71* 0.034
POD3 136.79 ± 23.34 155.38 ± 28.75* 0.012
POD7 51.83 ± 17.66 62.36 ± 18.37* 0.042
Variables were expressed as the mean ± SD
* P <0.05
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Discharge and follow-up
Patients were discharged only if they could tolerate a
semiliquid or soft diet and walk freely in the ward. Data
were collected prospectively and retrieved from our data-
base. Complete follow-up was available until 1 month
after surgery.
Statistical analysis
Outcome data were analyzed with the use of repeat
measurement ANOVA for continuous variables and chi-
square test or Fisher’s exact test for categorical variables.
All analyses were performed with the statistical package
SPSS (version 13.0; Chicago, IL). A P value of <0.05 was
considered significant.
Results
In all, 260 patients finished the study, including 128 pa-
tients in the FTS group and 132 patients in the conven-
tional group. Ten patients were excluded from the FTS
group and six patients from the conventional group (Fig. 1).
No significant differences were observed in sex, age, weight,
BMI, operating time, blood loss, operative incision, tumor
TNM stage, tumor pathology, tumor location and neoadju-
vant therapy between the two groups (Table 1).
Clinical parameters
Postoperative hospital stay in patients randomized to the
FTS group was significantly shorter than in the conven-
tional group (P < 0.05). The mean charge for periopera-
tive hospital stay was 35823.62 ± 3598.81 renminbi
(RMB) for the FTS group, which was significantly less
than the cost of 41032.73 ± 4013.32 RMB for the con-
ventional group (P <0.05). Incision pain according to the
Numeric Rating Scale was lower in patients of the FTS
group than in those of the conventional group (P <0.05).
And we had compared the degree of pain among three
different surgical approaches: pure video-assisted thor-
acic surgery (VATS), hybrid VATS, and conventional
thoracotomy. In the early postoperative period, pure
VATS was shown to be the least painful of the three sur-
gical approaches. No statistically significant differences
were detected in postoperative complications between
the two groups (P < 0.05). There was, however, a trend
toward more postoperative complications (9.8 %) in pa-
tients undergoing conventional pathway (Table 4). Ac-
cording to Clavien-Dindo classification, 11 (8.6 %)
patients in FTS group and 16 (12.1 %) patients in con-
ventional group suffered stageI, II and III complications
respectively. Two patient in FTS group and three patient
in the conventional group was diagnosed atrial
arrhythmia by an ECG recording (I). Two patient in FTS
group and two patient in the conventional group showed
incision infection (I). One patient in the conventional
group developed postoperative paralytic ileus and
Table 6 Comparison of immunologic factors in two groups






Before surgery 28.37 ± 3.93 27.32 ± 4.33 0.943
POD1 22.74 ± 3.93 22.39 ± 3.82 1.000
POD3 25.66 ± 2.94 22.21 ± 2.99* 0.038
POD7 29.95 ± 3.85 27.97 ± 4.41 0.537
IgG (g/l)
Before surgery 14.38 ± 2.78 15.33 ± 3.79 0.573
POD1 8.97 ± 1.79 6.11 ± 1.38* 0.033
POD3 11.02 ± 3.53 8.17 ± 2.94* 0.002
POD7 14.53 ± 3.81 13.02 ± 3.73 0.741
IgA (g/l)
Before surgery 2.79 ± 0.52 2.98 ± 0.35 0.757
POD1 1.81 ± 0.43 1.65 ± 0.17* 0.012
POD3 2.08 ± 0.54 1.76 ± 0.47* 0.003
POD7 2.58 ± 0.47 2.62 ± 0.39 0.637
IgM (g/l)
Before surgery 1.21 ± 0.35 1.24 ± 0.44 1.000
POD1 0.82 ± 0.39 0.89 ± 0.43 0.964
POD3 0.75 ± 0.22 0.77 ± 0.31 0.543
POD7 1.18 ± 0.59 1.23 ± 0.48 0.424
CD3
Before surgery 55.99 ± 2.72 57.83 ± 2.64 0.813
POD1 49.92 ± 2.75 46.01 ± 2.83* 0.042
POD3 51.83 ± 2.42 48.02 ± 2.51* 0.019
POD7 55.05 ± 2.69 53.83 ± 2.71 0.737
CD4
Before surgery 45.58 ± 3.92 44.97 ± 4.32 0.958
POD1 33.26 ± 4.72 30.37 ± 5.21* 0.039
POD3 39.39 ± 4.81 34.34 ± 5.72* 0.012
POD7 43.76 ± 4.38 42.87 ± 3.98 0.887
CD8
Before surgery 26.73 ± 4.85 26.08 ± 3.97 1.000
POD1 23.72 ± 4.33 24.42 ± 4.74 0.958
POD3 23.76 ± 3.83 22.73 ± 4.65 0.832
POD7 28.73 ± 4.38 27.62 ± 3.83 0.732
CD4/CD8
Before surgery 1.53 ± 0.33 1.48 ± 0.42 0.739
POD1 1.45 ± 0.31 1.22 ± 0.45* 0.042
POD3 1.52 ± 0.45 1.39 ± 0.30* 0.023
POD7 1.58 ± 0.32 1.53 ± 0.54 0.865
Variables were expressed as the mean ± SD
* P <0.05
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required reinsertion of a nasogastric tube, and this was
resolved by restricting intake and parenteral nutrition
(II). Three patients in FTS group and four patients in
the conventional group had pneumonia and this was re-
solved by physical therapy and antibiotic treatment (II).
Anastomotic leak occurred in two patient in FTS group
and three patients in the conventional group, and this
was resolved by endoscopic treatment (III). Two patients
in FTS group and three patients in the conventional
group had ARDS and were treated with mechanical ven-
tilation in the Intensive Care Unit (IV).
Pro-inflammatory parameters
On PODs 1 and 3, statistically significant differences
were found in levels of IL-6 and CRP with the FTS
group having lower levels than in the conventional
group (P <0.05). On POD 7, the level of CRP was lower
in the FTS group than that in the conventional group (P
<0.05) (Table 5).
Immunological parameters
There were no significant differences in the post-
operativelevel and pre-operative level of IgM and CD8
between the two groups. On PODs 1 and 3, statistically
significant differences were found in the levels of IgG,
IgA, CD3, CD4 and CD4/CD8 ratio with the FTS
group having higher levels than the conventional
group (all P <0.05). On POD 3, the level of serum
globulin was higher in the FTS group than that in
the conventional group (P <0.05) (Table 6). We per-
formed subgroup analysis based on neoadjuvant or
not, as well as MIE (Minimally invasive esophagectomy)
or not for avoiding bias, and we came to similar conclu-
sions after data analysis (Tables 7, 8, 9 and 10).
Discussion
Recent clinical data indicate that FTS leads to shorter
postoperative length of hospital stay, faster recovery of
gastrointestinal function as well as reduced morbidity
and mortality rates [1, 3, 4]. To date, no study has fo-
cused on the effects of FTS on immune function after
esophagectomy for esophageal cancer. This study was
initiated to determine whether FTS results in improved
Table 7 Comparison of inflammatory markers and immunologic
factors in two groups without neoadjuvant






Before surgery 52.13 ± 25.54 54.67 ± 22.36 0.651
POD1 123.43 ± 20.73 139.26 ± 22.92* 0.007
POD3 144.05 ± 26.39 156.25 ± 25.38* 0.032
POD7 117.23 ± 21.29 123.36 ± 25.56 0.321
CRP (mg/L)
Before surgery 4.92 ± 1.53 4.83 ± 1.72 0.953
POD1 66.37 ± 12.93 75.52 ± 14.88* 0.023
POD3 138.84 ± 22.04 156.58 ± 29.21* 0.019
POD7 53.84 ± 16.95 64.06 ± 16.74* 0.031
Globulin (g/l)
Before surgery 28.82 ± 3.93 27.97 ± 5.21 0.643
POD1 22.25 ± 3.83 21.09 ± 3.90 0.231
POD3 25.72 ± 3.08 22.68 ± 2.89* 0.026
POD7 28.56 ± 2.25 27.74 ± 4.04 0.447
IgG (g/l)
Before surgery 15.82 ± 2.98 14.18 ± 3.69 0.585
POD1 8.87 ± 1.65 6.32 ± 1.19* 0.025
POD3 10.88 ± 3.37 7.94 ± 2.87* 0.000
POD7 14.51 ± 2.83 13.97 ± 3.63 0.231
IgA (g/l)
Before surgery 2.76 ± 0.33 2.85 ± 0.27 0.654
POD1 1.71 ± 0.54 1.45 ± 0.14* 0.013
POD3 1.98 ± 0.47 1.67 ± 0.52* 0.002
POD7 2.53 ± 0.33 2.42 ± 0.38 0.585
IgM (g/l)
Before surgery 1.24 ± 0.33 1.19 ± 0.46 0.841
POD1 0.85 ± 0.49 0.81 ± 0.32 0.432
POD3 0.77 ± 0.17 0.71 ± 0.26 0.233
POD7 1.15 ± 0.53 1.21 ± 0.50 0.190
CD3+
Before surgery 57.92 ± 2.63 58.23 ± 2.48 0.764
POD1 48.87 ± 2.51 46.13 ± 2.78* 0.047
POD3 51.17 ± 2.20 48.19 ± 2.31* 0.013
POD7 55.59 ± 2.28 53.07 ± 2.84 0.230
CD4+
Before surgery 44.28 ± 3.48 44.73 ± 4.52 0.864
POD1 34.95 ± 4.72 31.07 ± 5.09* 0.020
POD3 38.52 ± 3.61 34.54 ± 5.22* 0.016
POD7 43.38 ± 5.86 42.48 ± 3.84 0.382
Table 7 Comparison of inflammatory markers and immunologic
factors in two groups without neoadjuvant (Continued)
CD4+/CD8+
Before surgery 1.64 ± 0.32 1.55 ± 0.49 0.872
POD1 1.43 ± 0.21 1.20 ± 0.51* 0.036
POD3 1.54 ± 0.55 1.41 ± 0.34* 0.018
POD7 1.57 ± 0.24 1.51 ± 0.28 0.341
Variables were expressed as the median ± quartile
* P <0.05
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clinical and immunological outcome of patients under-
going esophagectomy for esophageal cancer.
The normal inflammatory response, more commonly
known as the stress response, was first described by Sir
David Cuthbertson [5]. Despite variability in the inten-
sity of the stress response, the timeline of events remains
remarkably similar, with few exceptions. Virtually all
mediators of inflammation and metabolism peak about
postinjury day 2 and then return to baseline levels by
postinjury days 6–7. The inflammatory response may
obviously be important for wound healing and resistance
to infection, but on the other hand may have undesirable
effects by enhancing pain and leading to fatigue and
sleep disturbances [6]. Inflammation is triggered when
innate immune cells detect infection or tissue injury. We
found most of immune markers decreased under condi-
tion of the increase of pro-inflammatory cytokines. This
research into the mechanisms that immune impact may
provide a novel therapeutic pathway that can alter the
nature and time course of the stress response.
Perioperative intervention improvements that might
be contributed to the immunologic protection, including
taking a carbohydrate rich drink before surgery, early
enteral nutrition and epidural analgesia. Before surgery,
patients often already have poor nutritional status and
low immune function. For patients with esophageal can-
cer, their nutritional status will be worsened after surger-
ies, along with the decrease of the cellular and humoral
immunity [7]. Some studies indicated that taking a
carbohydraterich drink before surgery could reduce the
endocrine catabolic response and improve insulin resist-
ance, improving surgical results and hastening recovery
[8, 9]. Gut is regarded as a central organ after surgical
stress; also, among the intestinal mucosal barrier func-
tions, immune barrier plays an important role. the func-
tions of small intestine often return normal 6–12 h after
the surgery, which supports the early application of en-
teral nutrition (EN) after surgery [10]. Clinically, EN is
applied to facilitate the improvement of nutritional sta-
tus, restoration of immune function, and protection of
intestinal mucosal barrier after the surgeries. A recent
study verified that partial EN support during periopera-
tion will not only improve the postoperative nutritional
Table 8 Comparison of inflammatory markers and immunologic
factors in two groups with neoadjuvant






Before surgery 50.57 ± 21.45 51.42 ± 19.83 0.979
POD1 119.54 ± 18.62 131.42 ± 21.58* 0.004
POD3 138.42 ± 22.73 150.48 ± 21.97* 0.043
POD7 112.52 ± 19.43 116.43 ± 22.57 0.573
CRP (mg/L)
Before surgery 4.53 ± 1.24 4.45 ± 1.29 0.942
POD1 61.32 ± 13.77 70.52 ± 11.56* 0.032
POD3 132.73 ± 21.56 150.49 ± 25.72* 0.013
POD7 49.78 ± 15.84 60.43 ± 16.38* 0.035
Globulin (g/l)
Before surgery 25.67 ± 3.34 25.82 ± 4.39 1.000
POD1 21.43 ± 3.63 20.21 ± 3.45 0.760
POD3 24.76 ± 3.82 21.64 ± 2.94* 0.023
POD7 25.73 ± 3.35 25.87 ± 4.09 0.848
IgG (g/l)
Before surgery 13.76 ± 3.13 13.62 ± 3.42 0.858
POD1 7.42 ± 1.42 5.23 ± 1.35* 0.031
POD3 9.42 ± 3.53 6.44 ± 2.95* 0.001
POD7 12.56 ± 2.67 11.94 ± 3.83 0.656
IgA (g/l)
Before surgery 2.19 ± 0.29 2.21 ± 0.25 0.769
POD1 1.61 ± 0.37 1.34 ± 0.25* 0.017
POD3 1.85 ± 0.42 1.51 ± 0.51* 0.004
POD7 2.04 ± 0.37 2.15 ± 0.42 0.753
IgM (g/l)
Before surgery 1.14 ± 0.31 1.11 ± 0.41 0.893
POD1 0.71 ± 0.39 0.72 ± 0.33 0.957
POD3 0.67 ± 0.22 0.64 ± 0.32 0.873
POD7 1.09 ± 0.43 1.10 ± 0.42 0.673
CD3+
Before surgery 55.62 ± 2.43 56.82 ± 2.58 0.875
POD1 46.73 ± 2.52 44.09 ± 2.03* 0.043
POD3 49.82 ± 2.43 46.17 ± 2.35* 0.033
POD7 53.85 ± 2.05 54.04 ± 2.73 0.482
CD4+
Before surgery 42.43 ± 3.57 42.48 ± 4.92 0.803
POD1 32.52 ± 4.13 29.12 ± 5.02* 0.025
POD3 35.32 ± 3.90 32.55 ± 5.02* 0.013
POD7 41.42 ± 5.24 40.98 ± 4.27 0.484
Table 8 Comparison of inflammatory markers and immunologic
factors in two groups with neoadjuvant (Continued)
CD4+/CD8+
Before surgery 1.52 ± 0.41 1.55 ± 0.45 0.842
POD1 1.33 ± 0.36 1.11 ± 0.41* 0.027
POD3 1.47 ± 0.56 1.32 ± 0.37* 0.025
POD7 1.50 ± 0.36 1.52 ± 0.29 0.562
Variables were expressed as the median ± quartile
* P <0.05
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status and immune function, but also moderate the
inflammatory response of gastric cancer patients after
operative trauma [11]. Beier-Holgersen et al. [12] proved
early postoperative enteral nutrition had an important
influence on immediate unspecific cellular immunity
and had an activating effect on specific cellular immun-
ity. In our current randomized and controlled study, we
provided EN with postoperative patients in the FTS
group on POD1 and in the conventional group on
POD2. The immune globulins (IgA and IgG) and T
lymphocyte subsets (CD3, CD4 and CD4/CD8) at
POD1, 3 were higher in the FTS group than them in the
conventional group, showing a fast recovery of immun-
ity. We hypothesized that the fast recovery of immunity
might be ascribed to the fact that the earlier activation
of the immune system by earlier EN after surgery.
It has been verified that nociception and proinflamma-
tory cytokines play a mutual up-regulatory role [13].
Therefore, pain management may influence the immune
response in the postoperative period. It has been re-
ported that the alterations in lymphocyte subsets and
the increase in white cell counts induced by surgery and
general anesthesia can be prevented by epidural anal-
gesia [14, 15]. Furthermore, Beilin et al. [16] reported
that patients treated with patient-controlled analgesia
(PCA) exhibited attenuated proinflammatory cytokine
response in the postoperative period. Also Khaled et al.
[17] showed that thoracic epidural analgesia reduced the
systemic pro-inflammatory response and provided opti-
mal post-operative pain relief. In major surgery, however,
the effect of epidural anesthesia and analgesia on attenu-
ation of the stress response and preservation of immune
function is controversial.
The difference in immune function between the two
groups was also statistically significant. There are several
factors that may account for these differences. The dur-
ation of surgery and anesthesia, extent of tissue injury,
and blood loss are usually great in patients undergoing
esophagectomy. Blood transfusion is another factor in
inducing immunosuppression. There is increasing evi-
dence to suggest that perioperative blood transfusion
may have an immunomodulatory effect. A previous
study [18] of patients undergoing esophageal resection
Table 9 Comparison of inflammatory markers and immunologic
factors in two groups without MIE






Before surgery 53.26 ± 24.18 53.58 ± 23.14 0.842
POD1 123.73 ± 22.69 139.42 ± 24.78* 0.006
POD3 143.31 ± 25.42 155.79 ± 24.42* 0.043
POD7 117.73 ± 22.45 123.57 ± 23.84 0.571
CRP (mg/L)
Before surgery 4.94 ± 1.48 4.86 ± 1.32 0.943
POD1 66.42 ± 13.73 75.75 ± 13.57* 0.032
POD3 137.76 ± 24.73 156.79 ± 27.42* 0.015
POD7 52.75 ± 15.79 63.73 ± 15.2* 0.042
Globulin (g/l)
Before surgery 27.82 ± 3.59 28.71 ± 5.33 0.875
POD1 21.63 ± 3.54 21.79 ± 3.82 0.941
POD3 25.59 ± 3.14 22.79 ± 2.98* 0.043
POD7 28.73 ± 3.08 27.95 ± 4.24 0.545
IgG (g/l)
Before surgery 14.59 ± 3.28 13.97 ± 3.82 0.833
POD1 8.93 ± 1.59 6.47 ± 1.25* 0.034
POD3 10.51 ± 3.56 7.82 ± 2.96* 0.000
POD7 13.75 ± 2.97 13.66 ± 3.32 0.741
IgA (g/l)
Before surgery 2.65 ± 0.41 2.75 ± 0.32 1.000
POD1 1.78 ± 0.49 1.41 ± 0.25* 0.009
POD3 1.94 ± 0.46 1.65 ± 0.43* 0.004
POD7 2.43 ± 0.35 2.49 ± 0.41 0.842
IgM (g/l)
Before surgery 1.26 ± 0.41 1.21 ± 0.33 0.892
POD1 0.83 ± 0.38 0.85 ± 0.36 0.731
POD3 0.72 ± 0.19 0.71 ± 0.22 1.000
POD7 1.19 ± 0.49 1.24 ± 0.42 0.766
CD3+
Before surgery 58.03 ± 2.52 57.43 ± 2.67 0.852
POD1 48.93 ± 2.47 45.89 ± 2.49* 0.048
POD3 51.67 ± 2.33 47.87 ± 2.52* 0.011
POD7 54.68 ± 2.32 53.25 ± 2.93 0.473
CD4+
Before surgery 44.37 ± 3.52 44.52 ± 4.31 0.768
POD1 36.43 ± 4.28 32.66 ± 5.14* 0.028
POD3 39.13 ± 4.52 33.95 ± 5.38* 0.004
POD7 42.57 ± 4.38 42.64 ± 3.95 1.000
Table 9 Comparison of inflammatory markers and immunologic
factors in two groups without MIE (Continued)
CD4+/CD8+
Before surgery 1.59 ± 0.41 1.54 ± 0.43 0.892
POD1 1.47 ± 0.23 1.22 ± 0.41* 0.032
POD3 1.51 ± 0.45 1.40 ± 0.51* 0.012
POD7 1.54 ± 0.29 1.57 ± 0.21 0.842
Variables were expressed as the median ± quartile
* P <0.05
Chen et al. BMC Cancer  (2016) 16:449 Page 9 of 12
for carcinoma has demonstrated a significantly worse
prognosis for those receiving a blood transfusion inde-
pendent of disease stage or the presence of major
complications. It has been suggested that the immuno-
suppression induced by transfusion results from both an
early unspecific immunosuppression mediated by mono-
cytes and a later phase induced from increased suppres-
sor T cell activity. Blood transfusion has been shown to
lower the CD4 to CD8 ratio [19]. In addition, prosta-
glandin E2 levels are increased after transfusion [20].
This may result in a direct inhibition of interleukin-2
production from CD4 cells with subsequent effect, as
interleukin-2 is obligatory for natural killer cell activity.
In addition, it shows that transfusion of more than 3
units of blood can adversely affect survival [21]. There-
fore, every effort should be made to limit the amount of
blood transfused to the minimum requirement.
Cellular immunity is mediated by lymphocytes and
transferred by the cells of immunized people. Humoral
immunity is mediated by antibodies and transferred by
the sera of immunized people. Impairment of cellular
and humoral immune system may lead to infections sec-
ondary to surgery, progression of malign tumors, and
emergence of opportunistic infections. IL-6 is known to
be a major mediator of the acute-phase response and
plasma levels of IL-6 are reportedly related to the sever-
ity of surgical trauma [22]. It can stimulate the liver to
synthesize C-reactive protein (CRP), enhance inflamma-
tory reaction by promoting B cell differentiation and
antibody formation, and assist the T cells to produce the
expressions of IL-2 and its receptor [23]. In our current
study, no significant difference was found in both groups
of immunological parameters before surgery and POD7.
At PODs 1 and 3, the immune function indicators de-
creased in both groups. In the FTS group, the immune
globulins (IgA and IgG) and T lymphocyte subsets
(CD3, CD4 and CD4/CD8) were significantly higher than
those in the conventional group (P < 0.05), whereas IL-6
and CRP were significantly lower (P < 0.05). Therefore, the
FTS is helpful to improve the immune function in patients
undergoing esophagectomy for esophageal cancer.
Another powerful technique to reduce inflammatory re-
sponses is decreasing the wound size by minimal invasive
Table 10 Comparison of inflammatory markers and
immunologic factors in two groups with MIE






Before surgery 52.33 ± 24.37 53.42 ± 22.73 0.764
POD1 119.34 ± 21.57 134.42 ± 22.53* 0.005
POD3 140.05 ± 25.63 151.67 ± 24.52* 0.035
POD7 113.72 ± 22.42 117.66 ± 25.74 0.152
CRP (mg/L)
Before surgery 4.62 ± 1.63 4.53 ± 1.57 0.842
POD1 62.42 ± 13.83 71.42 ± 14.32* 0.027
POD3 134.73 ± 22.57 153.82 ± 25.62* 0.017
POD7 50.46 ± 15.73 61.43 ± 15.66* 0.012
Globulin (g/l)
Before surgery 27.72 ± 3.55 27.58 ± 5.14 0.942
POD1 23.57 ± 3.73 22.64 ± 3.73 0.543
POD3 25.42 ± 3.95 23.31 ± 3.52* 0.021
POD7 28.04 ± 2.76 27.87 ± 4.13 0.735
IgG (g/l)
Before surgery 14.63 ± 2.57 14.03 ± 3.1 0.872
POD1 9.43 ± 1.25 7.62 ± 1.17* 0.028
POD3 11.82 ± 3.52 8.73 ± 2.94* 0.002
POD7 14.42 ± 2.76 13.52 ± 3.33 0.542
IgA (g/l)
Before surgery 2.57 ± 0.31 2.77 ± 0.29 0.767
POD1 1.83 ± 0.41 1.54 ± 0.22* 0.015
POD3 1.99 ± 0.35 1.69 ± 0.42* 0.000
POD7 2.55 ± 0.32 2.52 ± 0.32 0.652
IgM (g/l)
Before surgery 1.28 ± 0.31 1.21 ± 0.36 0.853
POD1 0.94 ± 0.43 0.92 ± 0.35 0.482
POD3 0.87 ± 0.21 0.81 ± 0.32 0.353
POD7 1.25 ± 0.46 1.22 ± 0.52 0.320
CD3+
Before surgery 57.43 ± 2.82 58.12 ± 2.73 0.873
POD1 49.69 ± 2.43 47.02 ± 2.57* 0.044
POD3 53.38 ± 2.57 49.93 ± 2.65* 0.017
POD7 56.73 ± 2.52 56.48 ± 2.49 1.000
CD4+
Before surgery 44.52 ± 3.46 44.37 ± 4.41 1.000
POD1 35.87 ± 4.15 32.35 ± 4.89* 0.022
POD3 39.98 ± 3.73 35.43 ± 4.64* 0.013
POD7 44.73 ± 5.02 43.76 ± 3.92 0.859
Table 10 Comparison of inflammatory markers and
immunologic factors in two groups with MIE (Continued)
CD4+/CD8+
Before surgery 1.58 ± 0.30 1.52 ± 0.42 0.973
POD1 1.49 ± 0.24 1.26 ± 0.43* 0.031
POD3 1.64 ± 0.45 1.45 ± 0.28* 0.015
POD7 1.56 ± 0.32 1.50 ± 0.37 0.458
Variables were expressed as the median ± quartile
*P <0.05
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surgery. It is well established that this may reduce pain
and inflammatory responses especially proinflammatory
cytokines (IL-6 etc.) [24]. Inflammatory responses contrib-
ute to pain, fatigue and organ dysfunction. Minimally
invasive surgery also reduces the inflammatory response,
although the contribution that this plays in the context of
fast-track programmes in esophageal surgery is difficult to
interpret. We found that the immune function of patients
is mildly affected by minimally invasive surgery. No sig-
nificant differences were observed in immune function
between the minimally invasive surgery group and the
open surgery group. Of interest, a recent randomized
blinded study by Basse et al. showed that FTS leads to
similar clinical and functional results in patients undergo-
ing open as well as laparoscopic colorectal resections [25].
This indicates that the clinical advantages of laparoscopic
surgery may be of only minor importance for postopera-
tive recovery if the concept of FTS surgery is used for pa-
tients after major surgery. Minimal invasive surgery on a
procedure-specific basis therefore represent a major op-
portunity to further enhance recovery and reduce morbid-
ity in the future, especially when combined with other
aspects of the fast-track methodology.
Our results did not detect statistically significant
changes in serum IgM and CD8 lymphocytes between
the two groups. However, this does not mean that FTS
has no effects on these factors, which may be explained
by the time that blood samples were taken or the rela-
tively small number of cases in our trial. The above
factors may be differences between the two groups if we
increase the time that blood samples were taken, or
increase the amount of cases.
Only a small proportion of patients in our study
underwent Pure VATS surgery. We have not enough evi-
dence to demonstrate the effect of minimally invasive
surgery on immunity. Therefore, the changes of immune
indexes by laparoscopic and thoracoscopic surgery needs
to be investigated in further studies.
Conclusions
The beneficial clinical effects of FTS reported here
support the findings of other groups and our data on
perioperative immunity suggest that better-preserved
cellular and humoral immunity may contribute to the
improvement of postoperative results in fast-track pa-
tients. The precise mechanism of changes in immuno-
logical parameters in FTS needs further study.
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